Workflow
CHALKIS(000972)
icon
Search documents
中基健康(000972) - 2020 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - Operating revenue for the reporting period was CNY 42,964,683.12, an increase of 5,271.56% year-on-year[8] - Net profit attributable to shareholders of the listed company was CNY 2,667,106.83, with a year-to-date loss of CNY 42,077,086.68[8] - Basic earnings per share for the reporting period were CNY 0.003, compared to a loss of CNY 0.0546 in the same period last year[8] - The weighted average return on net assets was 0.61%, an increase of 1.76 percentage points year-on-year[8] - The company reported a net loss attributable to shareholders of ¥42,077,086.68, a decrease of 284.06% from a profit of ¥22,860,511.96 in the previous period[15] - The total comprehensive income decreased by 285.52% to -¥42,112,313.51 from ¥22,699,015.33, reflecting the overall financial downturn[15] - The company reported a net loss in retained earnings, increasing from CNY -1,437,437,657.71 to CNY -1,479,549,971.22, indicating a worsening of approximately 2.9%[33] - The company reported a net loss of CNY 42,112,313.51 for Q3 2020, compared to a net profit of CNY 22,699,015.33 in the same period last year, indicating a significant decline in profitability[48] - The total profit for the period was CNY -42,158,034.04, contrasting with a profit of CNY 23,365,182.52 in the prior year, highlighting a drastic shift in financial performance[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 669,410,187.63, a decrease of 9.57% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company were CNY 399,819,294.00, down 9.53% from the previous year[8] - Current assets decreased from CNY 336,301,718.81 to CNY 298,480,266.42, a reduction of about 11.3%[30] - Total liabilities decreased from CNY 292,346,652.15 to CNY 263,554,151.72, a decline of about 9.8%[32] - Non-current assets decreased from CNY 403,980,721.84 to CNY 370,929,921.21, a decline of about 8.2%[31] - The total equity attributable to shareholders decreased from CNY 441,936,607.51 to CNY 399,819,294.00, a reduction of approximately 9.5%[33] Cash Flow - The company reported a net cash flow from operating activities of CNY -1,669,475.90 for the reporting period[8] - The company's cash and cash equivalents decreased by 66.96% to ¥26,646,992.28 from ¥80,644,820.58 due to business transformation and debt repayment[15] - Cash flow from operating activities showed a net outflow of CNY -2,897,879.20, a significant decrease from a net inflow of CNY 54,803,106.71 in the same quarter last year[53] - The company received cash related to operating activities of ¥50,001,448.33, an increase of 91.26% from ¥26,143,150.72, indicating improved cash flow from operations[16] - The cash flow from investment activities showed a net outflow of -5,008,000.00 CNY, contrasting with a net inflow of 68,935,364.09 CNY in the previous period[58] - Cash flow from financing activities resulted in a net outflow of -48,005,077.36 CNY, compared to -120,469,078.30 CNY in the previous period, indicating improved cash management[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,141[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of the shares[11] Business Transformation and Strategy - The company plans to issue shares to raise funds for the modernization of traditional Chinese medicine and emergency medical supplies production, which will change its main business focus[17] - The company is focusing on market expansion and new product development as part of its strategic initiatives, although specific details were not disclosed in the report[48] - The company has not engaged in any securities or derivative investments during the reporting period[19][20] Operational Costs and Expenses - The total operating costs for the year-to-date were 70,506,467.43, compared to 232,818,833.74 in the previous year[47] - Management expenses increased to CNY 36,853,759.11 from CNY 29,580,073.59, indicating rising operational costs[48] - Research and development expenses for the third quarter amounted to 10,179,080.15, indicating ongoing investment in innovation[40] - Research and development expenses amounted to CNY 11,721,700.00, indicating ongoing investment in innovation despite financial losses[48] Other Financial Metrics - The company recorded other income of CNY 178,736.58, which was lower than the previous year's CNY 374,068.77, suggesting reduced ancillary income sources[48] - The company reported a credit impairment loss of -5,498,845.88 for the third quarter, reflecting challenges in asset quality[40] - The company incurred a credit impairment loss of CNY -16,521,669.99, which negatively impacted overall profitability[48] - There were no non-recurring gains or losses reported during the reporting period[8] Future Reporting and Standards - The company has not yet audited the third-quarter report, which may affect the reliability of the financial data presented[59] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[59]
中基健康(000972) - 2020 Q1 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for Q1 2020 was ¥2,758,230.08, a decrease of 96.99% compared to ¥91,484,302.22 in the same period last year[8] - The net profit attributable to shareholders was -¥13,041,004.34, representing a 45.43% increase in losses compared to -¥8,966,936.17 in the previous year[8] - The net profit decreased by 44.47% to -¥13,053,465.20 from -¥9,035,125.01, reflecting reduced income and increased expenses[15] - The net loss for Q1 2020 was CNY 13,053,465.20, compared to a net loss of CNY 9,035,125.01 in Q1 2019, reflecting an increase in losses of approximately 44%[35] - The total comprehensive income for the parent company in Q1 2020 was -¥13,041,004.34, compared to -¥8,966,936.17 in Q1 2019, indicating a significant decline in overall performance[36] - Basic and diluted earnings per share for Q1 2020 were both -¥0.0169, worsening from -¥0.0116 in Q1 2019[36] Cash Flow and Liquidity - The net cash flow from operating activities was -¥4,790,684.39, which is a 63.16% improvement from -¥13,002,306.18 in the same period last year[8] - Cash and cash equivalents decreased by 66.27% to ¥27,197,614.66 from ¥80,644,820.58 due to loan repayments[15] - Cash received from sales dropped by 99.98% to ¥4,000.00 from ¥21,623,066.04, indicating no product sales during the quarter[15] - The company's cash and cash equivalents dropped from CNY 68,436,735.75 at the end of 2019 to CNY 14,980,430.44 by March 31, 2020, a decrease of about 78%[30] - The company reported a total cash outflow from financing activities of -¥48,005,077.36 in Q1 2020, compared to -¥16,172,991.27 in the same period last year, indicating increased cash outflows related to financing[44] - The cash received from other operating activities was 20,175.53 yuan, a notable increase from the previous period[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥674,451,770.44, down 8.89% from ¥740,282,440.65 at the end of the previous year[8] - The total liabilities decreased from CNY 292,346,652.15 at the end of 2019 to CNY 239,569,447.14 by March 31, 2020, a reduction of about 18%[30] - The total equity attributable to shareholders decreased from CNY 441,936,607.51 at the end of 2019 to CNY 428,895,603.17 by March 31, 2020, a decline of approximately 3%[30] Operating Costs and Expenses - Operating costs decreased by 96.18% to ¥3,347,191.68 from ¥87,733,345.57, also due to factory shutdowns[15] - Management expenses increased by 35.12% to ¥11,382,896.18 from ¥8,424,348.49 due to costs associated with the shutdown[15] - The company incurred sales expenses of ¥20,832.67 in Q1 2020, up from ¥2,220.00 in Q1 2019, indicating increased costs associated with sales efforts[38] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,804[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of the shares[10] Other Information - The company reported no non-recurring gains or losses during the reporting period[8] - The company did not undergo an audit for the first quarter report[48] - The company has not applied new revenue and leasing standards for the current reporting period[48]
中基健康(000972) - 2021 Q1 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for Q1 2021 was 0.00, a decrease of 100.00% compared to 2,758,230.08 in the same period last year[8] - The net profit attributable to shareholders was -19,979,751.27, representing an increase of 53.21% from -13,041,004.34 year-on-year[8] - The basic earnings per share were -0.0259, a decline of 53.25% from -0.0169 in the same period last year[8] - The total profit loss increased by 53.13% to ¥-19,988,180.25 compared to ¥-13,053,465.20 in the previous year, reflecting the ongoing transformation and production halt[15] - The net profit for Q1 2021 was a loss of CNY 19,988,180.25, compared to a loss of CNY 13,053,465.20 in the same period last year, indicating an increase in losses of about 53.5%[39] - The total operating costs for Q1 2021 were CNY 20,017,428.02, an increase from CNY 15,920,524.82 in the previous year, representing a growth of approximately 25.8%[38] Cash Flow and Liquidity - The net cash flow from operating activities was -25,390,802.51, an increase of 430.00% compared to -4,790,684.39 in the previous year[8] - The cash inflow from operating activities totaled CNY 149,553.82 in Q1 2021, a decrease from CNY 733,296.72 in the previous year[45] - Total cash outflow from operating activities amounted to 25,540,356.33 CNY, while cash inflow was only 1,581,660.56 CNY, resulting in a negative cash flow situation[49] - The ending cash and cash equivalents balance decreased to 10,548,551.53 CNY from 37,016,403.17 CNY at the beginning of the period, indicating a cash depletion of 26,467,851.64 CNY[47] - The company’s cash and cash equivalents decreased significantly from CNY 366,012.44 to CNY 16,884.87, a decline of approximately 95.4%[32] - The company’s cash and cash equivalents decreased by 71.32% to ¥10,613,891.89 from ¥37,007,442.78 due to a transformation and production halt[15] Assets and Liabilities - The total assets at the end of the reporting period were 562,832,228.58, down 3.38% from 582,505,841.85 at the end of the previous year[8] - The total liabilities increased slightly from CNY 401,294,652.22 to CNY 401,609,219.20, an increase of about 0.8%[31] - The company’s total equity decreased from CNY 181,211,189.63 to CNY 161,223,009.38, a decline of approximately 11%[32] - The total current liabilities increased from CNY 245,683,431.85 to CNY 245,963,265.50, an increase of about 0.1%[31] - The total non-current assets slightly increased from CNY 361,212,417.84 to CNY 362,306,880.74, an increase of about 0.3%[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,156[10] - The top shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of shares[10] Operational Changes - The company is currently undergoing a transformation and production halt, impacting all major financial metrics significantly[15] - Management expenses increased by 63.99% to ¥18,666,259.97, attributed to fixed asset depreciation[15] - The company reported no non-recurring gains or losses during the reporting period[8] - The company did not report any cash inflow from investment activities, highlighting a lack of investment recovery during the quarter[50] - The company reported a credit impairment loss of CNY 25,000.00 in Q1 2021, compared to no such loss in the previous year[38] Tax and Financial Expenses - The company reported a 260.97% increase in tax payments to ¥9,401,699.46, due to tax liabilities from December 2020[17] - The financial expenses for Q1 2021 were CNY 1,345,108.05, up from CNY 1,072,145.61 in the previous year, indicating an increase of about 25.3%[38]
中基健康(000972) - 2021 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for the third quarter was ¥4,233,801.45, a decrease of 90.15% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,548,581.94, with a year-to-date loss of ¥54,849,067.67, representing a 30.35% increase in losses year-on-year[4] - Total operating revenue for the period was CNY 7,359,465.17, a decrease of 83.93% compared to CNY 45,786,377.20 in the previous period[20] - The net profit for Q3 2021 was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the previous year, reflecting a worsening financial position[22] - The total comprehensive income for the period was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the same quarter last year[22] - Basic and diluted earnings per share were both reported at CNY -0.0711, compared to CNY -0.0546 in the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was -¥260,820,543.21, an increase of 8,900.39% compared to the previous year[4] - Cash received from operating activities decreased by 75.85% to ¥12,072,906.77 compared to the previous year[8] - The cash flow from operating activities showed a net outflow of CNY 260,820,543.21, compared to a smaller outflow of CNY 2,897,879.20 in the same quarter last year[25] - The company reported a cash inflow from financing activities of CNY 275,587,666.68, a significant increase from a cash outflow of CNY 48,005,077.36 in the previous year[26] - The company’s cash and cash equivalents at the end of the period totaled CNY 50,547,571.13, an increase from CNY 26,646,992.28 at the end of the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥863,303,440.02, an increase of 48.21% from the end of the previous year[4] - The company reported a total liability of CNY 736,968,339.48, compared to CNY 401,294,652.22 in the previous year[18] - Current assets totaled CNY 534,939,116.31, significantly up from CNY 221,293,424.01 at the end of 2020[16] - Total current liabilities rose to CNY 583,356,969.11 from CNY 245,683,431.85[18] - The company's equity attributable to shareholders decreased by 31.16% to ¥121,194,771.79 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased to CNY 121,194,771.79 from CNY 176,043,839.46[18] Shareholder Information - The company had a total of 30,017 common shareholders at the end of the reporting period[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Research and Development - Research and development expenses were reduced to ¥0.00 from ¥11,721,700.00 in the previous year, indicating a 100% decrease[7] - The company did not report any research and development expenses in Q3 2021, compared to CNY 11,721,700.00 in the same period last year[21] Operational Changes - The company reported a significant increase in accounts payable, which rose by 139.16% to ¥77,658,590.11 due to the resumption of production[7] - The total operating costs amounted to CNY 54,662,671.06, with operating costs specifically at CNY 7,873,335.63, down from CNY 17,470,147.34 year-over-year[21] - The company’s management expenses rose to CNY 40,941,641.91, up from CNY 36,853,759.11 year-over-year[21] - Inventory reached CNY 290,514,718.50, indicating a new addition as there was no inventory reported in the previous period[16] Legal and Regulatory Issues - The company is facing a court-ordered freeze on dividends amounting to CNY 123,970,926.36 for a period of three years[12]
中基健康(000972) - 2021 Q2 - 季度财报
2021-08-26 16:00
Financial Performance - The company's operating revenue for the first half of 2021 was ¥3,125,663.72, representing a 10.77% increase compared to ¥2,821,694.08 in the same period last year[21]. - The net profit attributable to shareholders was -¥46,300,485.73, slightly worse than -¥44,744,193.51 in the previous year[21]. - The net cash flow from operating activities was -¥18,531,697.98, compared to -¥6,808,897.15 in the same period last year[21]. - Total assets decreased by 7.53% to ¥538,653,747.66 from ¥582,505,841.85 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 26.30% to ¥129,743,353.73 from ¥176,043,839.46 at the end of the previous year[21]. - The weighted average return on net assets was -30.28%, an increase of 19.62 percentage points compared to -10.66% in the previous year[21]. - The company reported a net profit of -28.8 million for the period, indicating ongoing financial challenges[45]. - The company reported a total comprehensive loss of -46,321,199.04 CNY for the first half of 2021, compared to -44,769,204.53 CNY in the same period last year, representing an increase in losses of about 3.5%[113]. - The company's operating profit for the first half of 2021 was -46,982,640.85 CNY, compared to -44,833,816.31 CNY in the same period of 2020, indicating a decline of approximately 4.8%[113]. - The total liabilities as of June 30, 2021, amounted to CNY 403,763,757.07, slightly up from CNY 401,294,652.22 at the end of 2020[106]. Cash Flow and Liquidity - Cash and cash equivalents decreased significantly from CNY 37,007,442.78 to CNY 15,530,753.63, representing a decline of approximately 58.0%[103]. - The cash flow from operating activities for the first half of 2021 was -18,531,697.98 CNY, worsening from -6,808,897.15 CNY in the first half of 2020[120]. - The company had a cash and cash equivalents balance of 15,530,253.63 CNY at the end of the first half of 2021, down from 24,707,597.07 CNY at the end of the same period in 2020, a decrease of approximately 37.1%[121]. - The company reported a total cash outflow from investing activities of 214,751.73 yuan, compared to 5,003,000.00 yuan in the first half of 2020, reflecting a significant reduction in investment spending[124]. - The company's cash flow from operating activities showed a significant decrease in cash inflow from 488,111.74 yuan in the first half of 2020 to 10,259,380.76 yuan in the first half of 2021[123]. Operational Strategy and Future Plans - The company has initiated the recovery of tomato production and is organizing production work to gradually restore factory output and cost plans[28]. - The company plans to gradually restore production in its tomato industry, with expectations of improved market conditions for tomato sauce in the future[47]. - The company aims to optimize its product structure by focusing on high-value tomato lycopene health products[47]. - The company is committed to improving its capital operation efficiency and exploring long-term incentive mechanisms for employees[48]. - The company plans to enhance resource integration and reduce burdens by leasing assets, specifically through a contract for 87 tomato harvesters[80]. - The company aims to enhance its talent training system and recruitment mechanisms to improve management levels and overall employee quality[156]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 31,341[90]. - The largest shareholder, Xinjiang Production and Construction Corps, holds 16.18% of the shares, totaling 124,769,223 shares[90]. - The total number of shares remains at 771,283,579, with no changes reported[88]. - The total equity attributable to the parent company decreased to CNY 129,743,353.73 from CNY 176,043,839.46 at the end of 2020, reflecting a decline of approximately 26.3%[106]. - The company reported a total of CNY 540,843,097.79 in other receivables as of June 30, 2021, down from CNY 546,630,845.03 at the end of 2020[109]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding its future plans and projections[5]. - The company has faced significant operational risks due to adverse weather conditions affecting tomato production[46]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[62]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[63]. - The company has no violations regarding external guarantees during the reporting period[64]. - The semi-annual financial report has not been audited[65]. Corporate Governance and Social Responsibility - The company is committed to enhancing the leadership role of the Party in state-owned enterprises and improving corporate governance to ensure sustainable development[155]. - The company actively participates in social responsibility initiatives, including poverty alleviation and supporting local agricultural development[58]. - The company emphasizes environmental protection and energy conservation as part of its operational strategy[58].
中基健康(000972) - 2021 Q1 - 季度财报
2021-04-29 16:00
Financial Performance - The company's operating revenue for Q1 2021 was 0.00, a decrease of 100.00% compared to 2,758,230.08 in the same period last year[8] - The net profit attributable to shareholders was -19,979,751.27, representing an increase in loss of 53.21% from -13,041,004.34 year-on-year[8] - The net cash flow from operating activities was -25,390,802.51, which is a significant decline of 430.00% compared to -4,790,684.39 in the previous year[8] - The basic earnings per share were -0.0259, a decrease of 53.25% from -0.0169 in the same period last year[8] - The total profit loss increased by 53.13% to ¥-19,988,180.25 compared to ¥-13,053,465.20 in the previous year, indicating ongoing financial challenges[15] - The total comprehensive loss for Q1 2021 was CNY 19,988,180.25, compared to a loss of CNY 13,053,465.20 in the same period last year, marking an increase in losses of approximately 53.5%[40] Assets and Liabilities - The total assets at the end of the reporting period were 562,832,228.58, down 3.38% from 582,505,841.85 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 11.35% to 156,064,088.19 from 176,043,839.46 at the end of the previous year[8] - Total liabilities increased slightly from CNY 401,294,652.22 to CNY 401,609,219.20, reflecting a growth of about 0.8%[31] - The company's total equity decreased from CNY 181,211,189.63 to CNY 161,223,009.38, representing a decline of approximately 11%[32] Cash Flow - The company's cash and cash equivalents decreased by 71.32% to ¥10,613,891.89 from ¥37,007,442.78 due to a transformation and production halt[15] - Cash inflows from operating activities totaled CNY 149,553.82, a significant decrease from CNY 733,296.72 in the previous year[45] - The net cash flow from investing activities was -732,049.14 CNY, with no cash inflow recorded from investment activities[46] - The net cash flow from financing activities was -344,999.99 CNY, compared to -48,005,077.36 CNY in the previous period, showing a reduction in cash outflow related to financing[47] - The ending balance of cash and cash equivalents was 10,548,551.53 CNY, down from 26,161,078.33 CNY in the previous period, indicating a decrease in liquidity[47] Operational Challenges - Operating revenue dropped to ¥0.00, a 100% decrease compared to ¥2,758,230.08 in the previous year, as the company is in a transformation and production halt[15] - Management expenses increased by 63.99% to ¥18,666,259.97, primarily due to fixed asset depreciation[15] - The company reported no non-recurring gains or losses during the reporting period[8] - The company incurred a credit impairment loss of CNY 25,000.00, compared to no losses in the previous year[39] - The company has been actively communicating with investors, responding to over 50 inquiries regarding production and operational status during the reporting period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,156[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Miscellaneous - The company has not engaged in any securities or derivative investments during the reporting period[20][21] - The company did not report any cash inflow from investment activities, indicating a lack of new investments during the period[48] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[51]
中基健康(000972) - 2020 Q4 - 年度财报
2021-04-22 16:00
Financial Performance - The company's operating revenue for 2020 was ¥22,966,067.61, a decrease of 89.23% compared to ¥213,188,826.11 in 2019[17]. - The net profit attributable to shareholders for 2020 was -¥265,892,768.05, compared to a profit of ¥4,975,779.02 in 2019[17]. - The net profit after deducting non-recurring gains and losses was -¥129,860,055.27, a 14.65% increase in losses compared to -¥113,681,230.79 in 2019[17]. - The net cash flow from operating activities was -¥9,889,117.18, a significant decline from ¥142,656,995.36 in 2019[17]. - The basic earnings per share for 2020 was -¥0.34, compared to ¥0.01 in 2019[17]. - The total assets at the end of 2020 were ¥582,505,841.85, down from ¥740,282,440.65 at the end of 2019[17]. - The net assets attributable to shareholders decreased by 60.17% to ¥176,043,839.46 from ¥441,936,607.51 in 2019[17]. - The company reported a weighted average return on net assets of -86.05% for 2020, a decrease of 87.18 percentage points compared to the previous year[17]. - The company reported a net profit attributable to shareholders of -265.89 million yuan for 2020, with total net assets of ¥176,043,839.46[38]. - The company reported a net profit of -266,724,598.87 CNY, with a net profit attributable to shareholders of -265,892,768.05 CNY, indicating significant financial challenges[92]. Operational Challenges - The company has been warned of delisting risk due to negative net profit and operating revenue below ¥100 million[5]. - The company faced significant operational challenges, including insufficient self-financing capacity and a shortage of operating funds due to continuous losses[39]. - The rental service sector showed a gross margin of -59.27%, indicating a significant increase in operating costs compared to the previous year[45]. - The company’s manufacturing segment reported zero revenue in 2020, down from ¥192,504,754.63 in 2019, indicating a complete halt in this area[42]. - The company has not proposed any cash dividend distribution plans for the past three years, indicating a focus on reinvestment[88]. Strategic Initiatives - The company plans to issue stocks to raise funds for the construction of a medical emergency material production base in Xinjiang, aiming to enhance its capabilities in the pharmaceutical and health technology sectors[29]. - The company is focusing on transforming its business towards pharmaceutical technology and health technology, aiming to create new profit growth points[29]. - The company aims to enhance its core competitiveness in the medical protection industry by improving product quality and expanding into international markets[32]. - The company plans to establish a 500-acre emergency medical supplies industrial park, aiming to complete the overall layout design in 2021 and initiate the construction of production facilities[77]. - The company intends to enhance its research and development capabilities by increasing investment and forming strategic alliances with universities and research institutions for innovative drug development[78]. Market and Industry Trends - The company anticipates a significant growth in the emergency medical materials sector, with an expected increase exceeding 1000% in 2020 due to the COVID-19 pandemic[32]. - The company is focused on developing emergency medical supplies production to improve its capacity for emergency medical reserves in Xinjiang and nationwide[79]. - The company reported a steady growth in the Chinese herbal medicine industry, with production reaching 424.3 million tons in 2017, up from 400.2 million tons in 2016[75]. - The market size of the Chinese herbal medicine industry expanded to 746 billion yuan by 2017, up from 600 billion yuan in 2014[75]. Governance and Management - The company has maintained a stable management team, with all current directors and executives holding 0 shares at the beginning and end of the reporting period, except for the CFO[141]. - The company is committed to transparency in its governance, as evidenced by the detailed reporting of management changes and shareholding status[142]. - The company has established a complete independent financial department with its own accounting system and tax obligations[170]. - The company has a well-structured corporate governance system that complies with relevant laws and regulations, with no significant discrepancies identified[169]. - The company has not reported any significant changes in shareholding among its independent directors during the reporting period[141]. Audit and Compliance - The audit firm Zhongxing Caiguanghua issued a non-standard audit report, highlighting significant uncertainties regarding the company's ability to continue as a going concern[92]. - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2020, with no major deficiencies identified[185]. - The audit opinion issued by Zhongxing Caiguanghua Accounting Firm was a qualified opinion with a paragraph on going concern uncertainty, highlighting potential doubts about the company's ability to continue operations[189]. - The audit identified significant risks related to potential misstatements due to fraud or error, necessitating thorough evaluation and testing of internal controls[196]. Employee and Workforce - The company employed a total of 52 staff members, with 21 being technical personnel and 7 financial personnel[163]. - The educational background of employees included 8 with postgraduate degrees, 17 with bachelor's degrees, and 18 with associate degrees[164]. - The company has established a fair and transparent performance evaluation standard and incentive mechanism for employee performance assessment and rewards[166]. - The company has implemented a training and re-education mechanism, focusing on enhancing the capabilities and qualities of all employees through a combination of internal and external training[166]. Shareholder Information - The total number of unrestricted shares is 771,283,579, representing 100.00% of the total shares[127]. - The total number of shareholders at the end of the reporting period is 33,081[129]. - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., holds 16.18% of the shares, totaling 124,769,223 shares[129]. - The company has not reported any share buyback progress or changes in share transfer situations[127].
中基健康(000972) - 2020 Q3 - 季度财报
2020-10-28 16:00
Financial Performance - Operating revenue for the reporting period was ¥42,964,683.12, an increase of 5,271.56% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company was ¥2,667,106.83, with a year-to-date loss of ¥42,077,086.68[9]. - Basic earnings per share for the reporting period were ¥0.003, compared to a loss of ¥0.0546 in the same period last year[9]. - The weighted average return on net assets was 0.61%, an increase of 1.76 percentage points year-on-year[9]. - The company reported a net loss attributable to shareholders of ¥42,077,086.68, a decrease of 284.06% from a profit of ¥22,860,511.96 in the previous period[16]. - The total comprehensive income decreased by 285.52% to a loss of ¥42,112,313.51 from a profit of ¥22,699,015.33 in the previous period[16]. - The company reported a net loss of CNY 42,112,313.51 for Q3 2020, compared to a net profit of CNY 22,699,015.33 in the same period last year, indicating a significant decline in profitability[49]. Assets and Liabilities - Total assets at the end of the reporting period were ¥669,410,187.63, a decrease of 9.57% compared to the end of the previous year[9]. - Net assets attributable to shareholders of the listed company were ¥399,819,294.00, down 9.53% year-on-year[9]. - Total liabilities decreased from CNY 292,346,652.15 to CNY 263,554,151.72, a decline of about 9.8%[33]. - The company’s non-current assets decreased from CNY 403,980,721.84 to CNY 370,929,921.21, a reduction of approximately 8.2%[32]. - The company’s accounts payable increased by 131.15% to ¥64,724,799.20 from ¥28,000,855.36, indicating outstanding payments for outsourced services[16]. Cash Flow - The company reported a net cash flow from operating activities of -¥1,669,475.90 for the reporting period[9]. - Cash received from sales of goods and services dropped by 86.31% to ¥14,893,861.00 from ¥108,777,383.74, reflecting the impact of business transformation[17]. - The company generated CNY 64,895,309.33 in cash inflows from operating activities, down from CNY 135,028,231.07 in the previous year[54]. - The net cash flow from operating activities was -63,094,886.90 CNY, compared to -36,717,135.48 CNY in the previous period, indicating a significant increase in cash outflow[59]. - The company reported a total cash outflow of 86,593,897.30 CNY from operating activities, which is significantly higher than the previous period's outflow of 53,723,430.56 CNY[59]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,141[11]. - The top ten shareholders held a combined 42.70% of the company's shares, with the largest shareholder holding 16.18%[12]. Business Transformation and Strategy - The company plans to issue shares to raise funds for the modernization of traditional Chinese medicine and emergency medical supplies production, which will change its main business focus[18]. - The company is focusing on market expansion and new product development as part of its strategic initiatives[41]. Research and Development - Research and development expenses for Q3 2020 were CNY 10,179,080.15, indicating ongoing investment in innovation[41]. - Research and development expenses amounted to CNY 11,721,700.00, reflecting the company's commitment to innovation despite financial losses[49]. Audit and Verification - The report was not audited, indicating that the figures presented may be subject to further verification[60].
中基健康(000972) - 2020 Q2 - 季度财报
2020-08-30 16:00
Financial Performance - The company's operating revenue for the first half of 2020 was ¥2,821,694.08, a decrease of 98.59% compared to ¥200,278,061.07 in the same period last year[18]. - The net profit attributable to shareholders was a loss of ¥44,744,193.51, compared to a profit of ¥28,211,162.65 in the previous year[18]. - The net cash flow from operating activities was a negative ¥6,808,897.15, down from a positive ¥33,811,759.18 in the same period last year[18]. - Total revenue for the reporting period was CNY 2,821,694.08, a decrease of 98.59% compared to CNY 200,278,061.07 in the same period last year, primarily due to factory shutdowns[35]. - The company's net profit attributable to shareholders was CNY -44,744,193.51, with net assets amounting to CNY 397,192,414.00[34]. - The net loss for the first half of 2020 was CNY 44,769,204.53, compared to a net profit of CNY 28,125,891.52 in the first half of 2019, marking a shift of approximately 258.5%[131]. - The total comprehensive loss for the first half of 2020 was CNY 44,769,204.53, compared to a comprehensive income of CNY 28,125,891.52 in the first half of 2019[131]. - The total comprehensive income for the period was -44,744,193.51 CNY, a significant decrease compared to the previous period[148]. Assets and Liabilities - The total assets at the end of the reporting period were ¥658,171,568.81, a decrease of 11.09% from ¥740,282,440.65 at the end of the previous year[18]. - The company's current assets totaled CNY 277,493,814.29, down from CNY 336,301,718.81 at the end of 2019, indicating a decrease of about 17.4%[121]. - The total liabilities decreased from CNY 292,346,652.15 to CNY 255,004,984.84, a decline of approximately 12.8%[122]. - The company's equity attributable to shareholders decreased from CNY 441,936,607.51 to CNY 397,192,414.00, a reduction of about 10.1%[123]. - The total equity at the end of the reporting period was 696,904,112.88 CNY, reflecting a decrease from the previous period[165]. Operational Changes and Strategies - The company plans to suspend operations at its wholly-owned subsidiary, Hongse Fanqie Factory, to improve asset structure and reduce burdens[26]. - The company is actively working on reforming its subsidiaries to enhance market competitiveness and improve asset utilization efficiency[26]. - The company plans to issue A-shares to raise funds primarily for the construction of a traditional Chinese medicine industrialization base and an emergency medical supplies production base, which will change its main business to medical and pharmaceutical industry development, production, processing, and wholesale[34]. - The company is enhancing its internal vitality and market competitiveness through ongoing reforms and asset optimization[33]. - The company aims to improve its core competitiveness and profitability through strategic adjustments and operational direction changes[57]. - The company plans to leverage capital market financing and restructuring to enhance risk resistance and create new profit growth points[48]. - The company is committed to improving its talent training and recruitment mechanisms to optimize its talent structure and management team[58]. Legal and Compliance Issues - The company faced a significant loss of 113,681,230.79 CNY in net profit attributable to shareholders after deducting non-recurring gains and losses[57]. - The company has faced significant legal disputes with Tianjin Master Printing and Packaging Co., with claims totaling approximately 67.88 million yuan for management fees, inventory losses, and tax credits[66]. - The court ruled that Tianjin Master Printing must pay 9.99 million yuan in management fees and 18.1 million yuan in inventory losses, along with interest[66]. - The company filed an appeal to the Higher People's Court of Xinjiang Uygur Autonomous Region after the initial court rejected its lawsuit[70]. - There were no penalties or rectifications during the reporting period[72]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 35,480[101]. - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., holds 124,769,223 shares, accounting for 16.18% of total shares[103]. - The total number of shares before and after the recent changes remains at 771,283,579, with no new shares issued or repurchased[98]. - The company does not have any preferred shares or convertible bonds in the reporting period[107][110]. - There were no changes in the shareholding of directors, supervisors, and senior management during the reporting period[112]. Financial Reporting and Compliance - The financial report for the first half of 2020 was not audited, which may affect the reliability of the financial data presented[118]. - The financial statements comply with the requirements of the enterprise accounting standards, accurately reflecting the company's financial position as of June 30, 2020, and the operating results and cash flows for the first half of 2020[174]. - The company's accounting period is based on the calendar year, running from January 1 to December 31[175]. - The company uses Renminbi as its functional currency for accounting purposes[176]. Research and Development - Research and development expenses increased to CNY 1,542,619.85, reflecting the establishment of a new R&D center and associated personnel costs[35]. - The company has established four new pharmaceutical companies focused on technology research and sales in the health sector[49]. - The company has established four pharmaceutical companies focusing on technology research and sales in the health sector, leveraging the rich medicinal resources in Xinjiang[58]. Corporate Governance - The company emphasizes the importance of strengthening its political core and enhancing party leadership within state-owned enterprises[48]. - The company is focused on enhancing its operational efficiency and modern corporate governance as part of the state-owned enterprise reform pilot[58]. - The board believes that the company can improve its operating conditions and reduce losses through strategic adjustments and operational measures[59]. - The board of directors will continue to monitor and support management in enhancing the company's operational capacity[173].
ST中基:关于参加2020年新疆辖区上市公司投资者网上集体接待日活动的公告
2020-06-18 11:31
证券代码:000972 证券简称:ST中基 公告编号:2020-032号 中基健康产业股份有限公司关于 参加 2020 年新疆辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、误导性陈述或 者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资计划、 股权激励、可持续发展等投资者所关心的问题,公司定于2020年6月24日下午 15:00-17:30参加由新疆上市公司协会联合深圳市全景网络有限公司组织开展的2020 年新疆辖区上市公司投资者网上集体接待日活动。现将有关事项公告如下: 本次集体接待日活动将在深圳全景网络有限公司提供的网上平台,采取网络远程 的方式举行,投资者可以登录"全景路演天下"网站(http://rs.p5w.net/)或关注 微信公众号:全景财经(微信号:p5w2012),参与公司本次投资者集体接待日活动, 活动时间为 2020 年 6 月 24 日(星期三)15:00-17:30。 出席本次集体接待日的人员有:公司总经理孔繁立先生、董事会秘书邢江先生。 欢迎广大投资者积极参与。 特此公告。 中基健康产业 ...